查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1822447

2032 年神经病学个人化医疗市场预测：按治疗类型、技术、应用、最终用户和地区进行的全球分析

Personalized Medicine in Neurology Market Forecasts to 2032 - Global Analysis By Therapy Type (Pharmacogenomics, Digital Therapeutics, Biomarker-Based Diagnostics and Targeted Therapeutics), Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球神经病学个人化医疗市场预计在 2025 年达到 5,768 亿美元，到 2032 年将达到 1,0211 亿美元，预测期内的复合年增长率为 8.5%。

神经病学领域的精准医疗是一种以患者为中心的方法，根据个体独特的基因、生物标记、环境和生活方式特征，量身定制诊断、治疗和预防策略。它突破了「一刀切」的模式，整合了基因组学、神经影像学和数据分析等先进技术，以从个体层面理解疾病机制。这种方法提高了癫痫、阿兹海默症和多发性硬化症等神经系统疾病的精准治疗，改善了疗效并最大限度地减少了副作用。个人化神经病学也有助于早期发现和标靶治疗，使临床医生能够根据每位患者的神经系统状况，提供更有效、更可预测、更个人化的治疗方案。

神经系统疾病盛行率上升

神经系统疾病的日益流行加速了个人化医疗的发展，使神经病学成为一个更精准、以病人为中心的领域。在日益增长的需求驱动下，研究人员正在利用基因、生物标记和生活方式数据，为阿兹海默症和帕金森氏症等疾病制定个人化治疗方案。这种转变正在推动诊断和治疗领域的创新，使临床医生能够提供更有效、更个人化的护理，最终改善数百万神经系统疾病患者的治疗效果和生活品质。

个人化医疗高成本

神经病学个人化医疗的高昂成本严重阻碍了治疗的可及性和公平性。许多患者，尤其是资源匮乏地区的患者，无力负担先进的基因组检测和个人化医疗费用，导致治疗结果有差异。这一经济障碍减缓了个人化医疗的普及，限制了临床试验，并阻碍了可扩展解决方案的投资。最终，它损害了个人化医疗为所有人提供精准有效的神经系统治疗的前景。

基因组学和分子诊断学的进展

基因组学和分子诊断技术的进步使得准确识别基因突变和生物标记物成为可能，彻底改变了神经病学领域的个人化医疗。这些创新使得癫痫、阿兹海默症和帕金森氏症等疾病的个人化治疗成为可能，提高了疗效并减少了副作用。早期诊断和风险预测增强了主动护理，而基因标靶治疗则为以前无法治癒的疾病带来了希望。这些进步共同推动着神经医疗保健向个人化、数据主导的转型。

复杂的监管格局

复杂的监管环境严重阻碍了神经病学个人化医疗的发展。严格的核准流程、碎片化的全球标准以及对新兴技术的缓慢适应，阻碍了创新和病患可及性。基因数据和生物标记方面的监管模糊性，进一步加剧了临床整合的复杂性。这些障碍抑制了投资，阻碍了研究合作，限制了个人化治疗方案，并最终阻碍了为最需要的患者提供精准有效的神经系统治疗。

COVID-19的影响

COVID-19疫情凸显了精准医疗和远距离诊断的必要性，加速了神经学领域个人化医疗的应用。儘管医疗服务中断，远距远端医疗、数位健康平台和基因组研究领域的技术创新仍推动了个人化神经病学治疗的发展。然而，资源转移和临床试验的延迟暂时阻碍了治疗进展。整体而言，这场危机凸显了个人化治疗在神经系统疾病治疗中的价值，并增强了医疗服务的韧性和适应性。

阿兹海默症预计将成为预测期内最大的细分市场

由于对更有效的个人化医疗的迫切需求，预计阿兹海默症领域将在预测期内占据最大的市场份额。个人化医疗利用基因组学和生物标记来实现早期发现和个人化治疗策略，这对于控制阿兹海默症的进展尤其重要。随着研究投入的增加和技术的进步，该领域将受益于精准诊断和有针对性的干预措施，从而显着改善患者的治疗效果，并减轻看护者和医疗保健系统的负担。

预计微阵列领域在预测期内将实现最高复合年增长率

微阵列技术能够同时分析数千个基因标记，预计在预测期内将达到最高成长率。该技术在识别疾病特异性生物标记物和根据个别神经系统特征制定治疗方案方面发挥关键作用。它在临床环境中日益广泛地应用于早期诊断和个人化医疗，这正在提升其市场潜力。随着精准医疗需求的不断增长，微阵列技术提供了一种可扩展且经济高效的解决方案，以支援个人化神经病学应用的扩展。

比最大的地区

在预测期内，亚太地区预计将占据最大的市场份额，这得益于其庞大的患者群体、不断增长的医疗保健投入以及人们对神经系统疾病的认识不断提高。中国、印度和日本等国家正迅速采用先进的诊断技术和个人化医疗方法。政府推动基因组研究和医疗保健数位化的倡议也进一步推动了市场成长。该地区不断扩展的医疗保健基础设施和日益增长的个人化医疗需求是全球神经病学个人化医疗格局的关键驱动力。

复合年增长率最高的地区：

预计北美地区在预测期内将实现最高的复合年增长率，这得益于其强大的科研基础设施、高昂的医疗支出以及对创新技术的早期应用。该地区受益于学术机构、生物技术公司和医疗保健提供者之间的紧密合作，加速了基因组和分子诊断工具的开发。良好的法律规范以及阿兹海默症和多发性硬化症等神经系统疾病的盛行率不断上升，进一步推动了个人化医疗的需求，使北美成为成长的领头羊。

免费客製化服务：

此报告的订阅者可以使用以下免费自订选项之一：

  • 公司简介
    • 对最多三家其他市场公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球神经病学个人化医疗市场（依治疗类型）

  • 药物基因组学
  • 数位治疗学
  • 基于生物标记的诊断
  • 标靶治疗药物

6. 全球神经病学个人化医疗市场（按技术）

  • 次世代定序（NGS）
  • 基于CRISPR的诊断
  • 聚合酵素链锁反应（PCR）
  • 微阵列
  • 其他技术

7. 全球神经病学个人化医疗市场（按应用）

  • 阿兹海默症
  • 多发性硬化症
  • 帕金森氏症
  • 癫痫
  • 中风
  • 其他用途

8. 全球神经病学个人化医疗市场（依最终用户）

  • 医院和诊所
  • 研究机构
  • 诊断实验室
  • 製药和生物技术公司

9. 全球神经病学个人化医疗市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章：重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • Roche Holding AG
  • Thermo Fisher Scientific Inc.
  • Novartis AG
  • Becton, Dickinson and Company（BD）
  • Biogen Inc.
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Siemens Healthineers
  • Pfizer Inc.
  • Abbott Laboratories
  • GlaxoSmithKline plc（GSK）
  • Eli Lilly and Company
  • Amgen Inc.
  • Illumina, Inc.
  • Neurocrine Biosciences, Inc.
  • QIAGEN NV
  • PerkinElmer, Inc.
  • Agilent Technologies, Inc.
Product Code: SMRC31202

According to Stratistics MRC, the Global Personalized Medicine in Neurology Market is accounted for $576.8 billion in 2025 and is expected to reach $1,021.1 billion by 2032 growing at a CAGR of 8.5% during the forecast period. Personalized medicine in neurology is a patient-centered approach that tailor's diagnosis, treatment, and prevention strategies to an individual's unique genetic, biomarker, environmental, and lifestyle profile. It moves beyond the "one-size-fits-all" model by integrating advanced technologies like genomics, neuroimaging, and data analytics to understand disease mechanisms at a personal level. This approach enhances precision in managing neurological disorders such as epilepsy, Alzheimer's disease, and multiple sclerosis, improving outcomes and minimizing side effects. Personalized neurology also fosters early detection and targeted therapies, empowering clinicians to deliver care that is more effective, predictive, and responsive to each patient's distinct neurological makeup.

Market Dynamics:

Driver:

Rising Prevalence of Neurological Disorders

The rising prevalence of neurological disorders is accelerating advancements in personalized medicine, transforming neurology into a more precise and patient-centric field. With increased demand, researchers are harnessing genetic, biomarker, and lifestyle data to tailor treatments for conditions like Alzheimer's and Parkinson's. This shift fosters innovation in diagnostics and therapeutics, empowering clinicians to deliver more effective, individualized care-ultimately improving outcomes and quality of life for millions affected by neurological diseases.

Restraint:

High Cost of Personalized Treatments

The high cost of personalized treatments in neurology significantly hinders accessibility and equity in care. Many patients, especially in low-resource settings, cannot afford advanced genomic testing or tailored therapies, leading to disparities in treatment outcomes. This financial barrier slows widespread adoption, limits clinical trials, and discourages investment in scalable solutions. Ultimately, it undermines the promise of personalized medicine to deliver precise, effective neurological care for all individuals.

Opportunity:

Advancements in Genomics and Molecular Diagnostics

Advancements in genomics and molecular diagnostics have revolutionized personalized medicine in neurology by enabling precise identification of genetic mutations and biomarkers. These innovations allow tailored treatments for conditions like epilepsy, Alzheimer's, and Parkinson's, improving efficacy and reducing side effects. Early diagnosis and risk prediction empower proactive care, while gene-targeted therapies offer hope for previously untreatable disorders. Together, they drive a transformative shift toward individualized, data-driven neurological healthcare.

Threat:

Complex Regulatory Landscape

The complex regulatory landscape significantly hampers the advancement of personalized medicine in neurology. Stringent approval processes, fragmented global standards, and slow adaptation to emerging technologies delay innovation and patient access. Regulatory ambiguity around genetic data and biomarkers further complicates clinical integration. These barriers discourage investment, stifle collaboration, and limit tailored treatment options, ultimately impeding progress in delivering precise, effective neurological care to patients who need it most.

Covid-19 Impact

The Covid-19 pandemic accelerated the adoption of personalized medicine in neurology by highlighting the need for precision care and remote diagnostics. It spurred innovation in telemedicine, digital health platforms, and genomic research, enabling tailored neurological treatments despite healthcare disruptions. However, resource diversion and delayed clinical trials temporarily hindered progress. Overall, the crisis underscored the value of individualized approaches in managing neurological conditions, fostering resilience and adaptability in care delivery.

The alzheimer's disease segment is expected to be the largest during the forecast period

The alzheimer's disease segment is expected to account for the largest market share during the forecast period, due to urgent need for more effective, individualized treatments. Personalized medicine enables early detection and tailored therapeutic strategies using genomics and biomarkers, which are especially critical in managing Alzheimer's progression. With increasing research investments and technological advancements, this segment benefits from precision diagnostics and targeted interventions, significantly improving patient outcomes and reducing the burden on caregivers and healthcare systems.

The microarray segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the microarray segment is predicted to witness the highest growth rate, due to its ability to analyze thousands of genetic markers simultaneously. This technology plays a pivotal role in identifying disease-specific biomarkers and tailoring treatments to individual neurological profiles. Its growing adoption in clinical settings for early diagnosis and personalized therapy selection enhances its market potential. As demand for precision medicine rises, microarrays offer scalable, cost-effective solutions that support the expansion of personalized neurology applications.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to its vast patient population, increasing healthcare investments, and growing awareness of neurological disorders. Countries like China, India, and Japan are rapidly adopting advanced diagnostic technologies and personalized treatment approaches. Government initiatives promoting genomics research and healthcare digitization further fuel market growth. The region's expanding medical infrastructure and rising demand for tailored therapies make it a key driver in the global neurology personalization landscape.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to robust research infrastructure, high healthcare spending, and early adoption of innovative technologies. The region benefits from strong collaborations between academic institutions, biotech firms, and healthcare providers, accelerating the development of genomic and molecular diagnostic tools. Favorable regulatory frameworks and increasing prevalence of neurological disorders like Alzheimer's and multiple sclerosis further boost demand for personalized treatments, positioning North America as a growth leader.

Key players in the market

Some of the key players profiled in the Personalized Medicine in Neurology Market include Roche Holding AG, Thermo Fisher Scientific Inc., Novartis AG, Becton, Dickinson and Company (BD), Biogen Inc., Merck & Co., Inc., Johnson & Johnson, Siemens Healthineers, Pfizer Inc., Abbott Laboratories, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Amgen Inc., Illumina, Inc., Neurocrine Biosciences, Inc., QIAGEN N.V., PerkinElmer, Inc. and Agilent Technologies, Inc.

Key Developments:

In August 2025, Novartis has entered a collaboration with BioArctic to harness their BrainTransporter platform, aiming to develop novel neurological therapeutics. BioArctic will combine its BrainTransporter technology with a Novartis proprietary antibody to generate drug candidates.

In July 2025, Novartis has entered a collaboration with BioArctic to harness their BrainTransporter platform, aiming to develop novel neurological therapeutics. BioArctic will combine its BrainTransporter technology with a Novartis proprietary antibody to generate drug candidates.

Therapy Types Covered:

  • Pharmacogenomics
  • Digital Therapeutics
  • Biomarker-Based Diagnostics
  • Targeted Therapeutics

Technologies Covered:

  • Next-Generation Sequencing (NGS)
  • CRISPR-based Diagnostics
  • Polymerase Chain Reaction (PCR)
  • Microarray
  • Other Technologies

Applications Covered:

  • Alzheimer's Disease
  • Multiple Sclerosis
  • Parkinson's Disease
  • Epilepsy
  • Stroke
  • Other Neurological Disorders

End Users Covered:

  • Hospitals & Clinics
  • Research Institutes
  • Diagnostic Laboratories
  • Pharmaceutical & Biotechnology Companies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Personalized Medicine in Neurology Market, By Therapy Type

  • 5.1 Introduction
  • 5.2 Pharmacogenomics
  • 5.3 Digital Therapeutics
  • 5.4 Biomarker-Based Diagnostics
  • 5.5 Targeted Therapeutics

6 Global Personalized Medicine in Neurology Market, By Technology

  • 6.1 Introduction
  • 6.2 Next-Generation Sequencing (NGS)
  • 6.3 CRISPR-based Diagnostics
  • 6.4 Polymerase Chain Reaction (PCR)
  • 6.5 Microarray
  • 6.6 Other Technologies

7 Global Personalized Medicine in Neurology Market, By Application

  • 7.1 Introduction
  • 7.2 Alzheimer's Disease
  • 7.3 Multiple Sclerosis
  • 7.4 Parkinson's Disease
  • 7.5 Epilepsy
  • 7.6 Stroke
  • 7.7 Other Neurological Disorders

8 Global Personalized Medicine in Neurology Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Research Institutes
  • 8.4 Diagnostic Laboratories
  • 8.5 Pharmaceutical & Biotechnology Companies

9 Global Personalized Medicine in Neurology Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Roche Holding AG
  • 11.2 Thermo Fisher Scientific Inc.
  • 11.3 Novartis AG
  • 11.4 Becton, Dickinson and Company (BD)
  • 11.5 Biogen Inc.
  • 11.6 Merck & Co., Inc.
  • 11.7 Johnson & Johnson
  • 11.8 Siemens Healthineers
  • 11.9 Pfizer Inc.
  • 11.10 Abbott Laboratories
  • 11.11 GlaxoSmithKline plc (GSK)
  • 11.12 Eli Lilly and Company
  • 11.13 Amgen Inc.
  • 11.14 Illumina, Inc.
  • 11.15 Neurocrine Biosciences, Inc.
  • 11.16 QIAGEN N.V.
  • 11.17 PerkinElmer, Inc.
  • 11.18 Agilent Technologies, Inc.

List of Tables

  • Table 1 Global Personalized Medicine in Neurology Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Personalized Medicine in Neurology Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 3 Global Personalized Medicine in Neurology Market Outlook, By Pharmacogenomics (2024-2032) ($MN)
  • Table 4 Global Personalized Medicine in Neurology Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
  • Table 5 Global Personalized Medicine in Neurology Market Outlook, By Biomarker-Based Diagnostics (2024-2032) ($MN)
  • Table 6 Global Personalized Medicine in Neurology Market Outlook, By Targeted Therapeutics (2024-2032) ($MN)
  • Table 7 Global Personalized Medicine in Neurology Market Outlook, By Technology (2024-2032) ($MN)
  • Table 8 Global Personalized Medicine in Neurology Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
  • Table 9 Global Personalized Medicine in Neurology Market Outlook, By CRISPR-based Diagnostics (2024-2032) ($MN)
  • Table 10 Global Personalized Medicine in Neurology Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
  • Table 11 Global Personalized Medicine in Neurology Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 12 Global Personalized Medicine in Neurology Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 13 Global Personalized Medicine in Neurology Market Outlook, By Application (2024-2032) ($MN)
  • Table 14 Global Personalized Medicine in Neurology Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
  • Table 15 Global Personalized Medicine in Neurology Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
  • Table 16 Global Personalized Medicine in Neurology Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
  • Table 17 Global Personalized Medicine in Neurology Market Outlook, By Epilepsy (2024-2032) ($MN)
  • Table 18 Global Personalized Medicine in Neurology Market Outlook, By Stroke (2024-2032) ($MN)
  • Table 19 Global Personalized Medicine in Neurology Market Outlook, By Other Neurological Disorders (2024-2032) ($MN)
  • Table 20 Global Personalized Medicine in Neurology Market Outlook, By End User (2024-2032) ($MN)
  • Table 21 Global Personalized Medicine in Neurology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 22 Global Personalized Medicine in Neurology Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 23 Global Personalized Medicine in Neurology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 24 Global Personalized Medicine in Neurology Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
  • Table 25 North America Personalized Medicine in Neurology Market Outlook, By Country (2024-2032) ($MN)
  • Table 26 North America Personalized Medicine in Neurology Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 27 North America Personalized Medicine in Neurology Market Outlook, By Pharmacogenomics (2024-2032) ($MN)
  • Table 28 North America Personalized Medicine in Neurology Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
  • Table 29 North America Personalized Medicine in Neurology Market Outlook, By Biomarker-Based Diagnostics (2024-2032) ($MN)
  • Table 30 North America Personalized Medicine in Neurology Market Outlook, By Targeted Therapeutics (2024-2032) ($MN)
  • Table 31 North America Personalized Medicine in Neurology Market Outlook, By Technology (2024-2032) ($MN)
  • Table 32 North America Personalized Medicine in Neurology Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
  • Table 33 North America Personalized Medicine in Neurology Market Outlook, By CRISPR-based Diagnostics (2024-2032) ($MN)
  • Table 34 North America Personalized Medicine in Neurology Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
  • Table 35 North America Personalized Medicine in Neurology Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 36 North America Personalized Medicine in Neurology Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 37 North America Personalized Medicine in Neurology Market Outlook, By Application (2024-2032) ($MN)
  • Table 38 North America Personalized Medicine in Neurology Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
  • Table 39 North America Personalized Medicine in Neurology Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
  • Table 40 North America Personalized Medicine in Neurology Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
  • Table 41 North America Personalized Medicine in Neurology Market Outlook, By Epilepsy (2024-2032) ($MN)
  • Table 42 North America Personalized Medicine in Neurology Market Outlook, By Stroke (2024-2032) ($MN)
  • Table 43 North America Personalized Medicine in Neurology Market Outlook, By Other Neurological Disorders (2024-2032) ($MN)
  • Table 44 North America Personalized Medicine in Neurology Market Outlook, By End User (2024-2032) ($MN)
  • Table 45 North America Personalized Medicine in Neurology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 46 North America Personalized Medicine in Neurology Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 47 North America Personalized Medicine in Neurology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 48 North America Personalized Medicine in Neurology Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
  • Table 49 Europe Personalized Medicine in Neurology Market Outlook, By Country (2024-2032) ($MN)
  • Table 50 Europe Personalized Medicine in Neurology Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 51 Europe Personalized Medicine in Neurology Market Outlook, By Pharmacogenomics (2024-2032) ($MN)
  • Table 52 Europe Personalized Medicine in Neurology Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
  • Table 53 Europe Personalized Medicine in Neurology Market Outlook, By Biomarker-Based Diagnostics (2024-2032) ($MN)
  • Table 54 Europe Personalized Medicine in Neurology Market Outlook, By Targeted Therapeutics (2024-2032) ($MN)
  • Table 55 Europe Personalized Medicine in Neurology Market Outlook, By Technology (2024-2032) ($MN)
  • Table 56 Europe Personalized Medicine in Neurology Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
  • Table 57 Europe Personalized Medicine in Neurology Market Outlook, By CRISPR-based Diagnostics (2024-2032) ($MN)
  • Table 58 Europe Personalized Medicine in Neurology Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
  • Table 59 Europe Personalized Medicine in Neurology Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 60 Europe Personalized Medicine in Neurology Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 61 Europe Personalized Medicine in Neurology Market Outlook, By Application (2024-2032) ($MN)
  • Table 62 Europe Personalized Medicine in Neurology Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
  • Table 63 Europe Personalized Medicine in Neurology Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
  • Table 64 Europe Personalized Medicine in Neurology Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
  • Table 65 Europe Personalized Medicine in Neurology Market Outlook, By Epilepsy (2024-2032) ($MN)
  • Table 66 Europe Personalized Medicine in Neurology Market Outlook, By Stroke (2024-2032) ($MN)
  • Table 67 Europe Personalized Medicine in Neurology Market Outlook, By Other Neurological Disorders (2024-2032) ($MN)
  • Table 68 Europe Personalized Medicine in Neurology Market Outlook, By End User (2024-2032) ($MN)
  • Table 69 Europe Personalized Medicine in Neurology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 70 Europe Personalized Medicine in Neurology Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 71 Europe Personalized Medicine in Neurology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 72 Europe Personalized Medicine in Neurology Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
  • Table 73 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Country (2024-2032) ($MN)
  • Table 74 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 75 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Pharmacogenomics (2024-2032) ($MN)
  • Table 76 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
  • Table 77 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Biomarker-Based Diagnostics (2024-2032) ($MN)
  • Table 78 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Targeted Therapeutics (2024-2032) ($MN)
  • Table 79 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Technology (2024-2032) ($MN)
  • Table 80 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
  • Table 81 Asia Pacific Personalized Medicine in Neurology Market Outlook, By CRISPR-based Diagnostics (2024-2032) ($MN)
  • Table 82 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
  • Table 83 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 84 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 85 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Application (2024-2032) ($MN)
  • Table 86 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
  • Table 87 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
  • Table 88 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
  • Table 89 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Epilepsy (2024-2032) ($MN)
  • Table 90 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Stroke (2024-2032) ($MN)
  • Table 91 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Other Neurological Disorders (2024-2032) ($MN)
  • Table 92 Asia Pacific Personalized Medicine in Neurology Market Outlook, By End User (2024-2032) ($MN)
  • Table 93 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 94 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 95 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 96 Asia Pacific Personalized Medicine in Neurology Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
  • Table 97 South America Personalized Medicine in Neurology Market Outlook, By Country (2024-2032) ($MN)
  • Table 98 South America Personalized Medicine in Neurology Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 99 South America Personalized Medicine in Neurology Market Outlook, By Pharmacogenomics (2024-2032) ($MN)
  • Table 100 South America Personalized Medicine in Neurology Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
  • Table 101 South America Personalized Medicine in Neurology Market Outlook, By Biomarker-Based Diagnostics (2024-2032) ($MN)
  • Table 102 South America Personalized Medicine in Neurology Market Outlook, By Targeted Therapeutics (2024-2032) ($MN)
  • Table 103 South America Personalized Medicine in Neurology Market Outlook, By Technology (2024-2032) ($MN)
  • Table 104 South America Personalized Medicine in Neurology Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
  • Table 105 South America Personalized Medicine in Neurology Market Outlook, By CRISPR-based Diagnostics (2024-2032) ($MN)
  • Table 106 South America Personalized Medicine in Neurology Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
  • Table 107 South America Personalized Medicine in Neurology Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 108 South America Personalized Medicine in Neurology Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 109 South America Personalized Medicine in Neurology Market Outlook, By Application (2024-2032) ($MN)
  • Table 110 South America Personalized Medicine in Neurology Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
  • Table 111 South America Personalized Medicine in Neurology Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
  • Table 112 South America Personalized Medicine in Neurology Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
  • Table 113 South America Personalized Medicine in Neurology Market Outlook, By Epilepsy (2024-2032) ($MN)
  • Table 114 South America Personalized Medicine in Neurology Market Outlook, By Stroke (2024-2032) ($MN)
  • Table 115 South America Personalized Medicine in Neurology Market Outlook, By Other Neurological Disorders (2024-2032) ($MN)
  • Table 116 South America Personalized Medicine in Neurology Market Outlook, By End User (2024-2032) ($MN)
  • Table 117 South America Personalized Medicine in Neurology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 118 South America Personalized Medicine in Neurology Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 119 South America Personalized Medicine in Neurology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 120 South America Personalized Medicine in Neurology Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
  • Table 121 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Country (2024-2032) ($MN)
  • Table 122 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 123 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Pharmacogenomics (2024-2032) ($MN)
  • Table 124 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
  • Table 125 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Biomarker-Based Diagnostics (2024-2032) ($MN)
  • Table 126 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Targeted Therapeutics (2024-2032) ($MN)
  • Table 127 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Technology (2024-2032) ($MN)
  • Table 128 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
  • Table 129 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By CRISPR-based Diagnostics (2024-2032) ($MN)
  • Table 130 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
  • Table 131 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 132 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 133 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Application (2024-2032) ($MN)
  • Table 134 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Alzheimer's Disease (2024-2032) ($MN)
  • Table 135 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
  • Table 136 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Parkinson's Disease (2024-2032) ($MN)
  • Table 137 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Epilepsy (2024-2032) ($MN)
  • Table 138 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Stroke (2024-2032) ($MN)
  • Table 139 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Other Neurological Disorders (2024-2032) ($MN)
  • Table 140 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By End User (2024-2032) ($MN)
  • Table 141 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 142 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 143 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 144 Middle East & Africa Personalized Medicine in Neurology Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)